Skip to main content
. 2020 Sep 24;160(1):455–458.e5. doi: 10.1053/j.gastro.2020.09.028

Figure 1.

Figure 1

Logistic regression analysis of the association between acid-suppressive therapy and the risk of SARS-CoV-2 infection in the (A) whole cohort after PSM and (B) among participants with upper gastrointestinal diseases after PSM (∗P < .1). Cox regression analysis of the association between acid-suppressive therapy and the risk of death in (C) patients with COVID-19 after PSM (∗P < .1) and (D) in COVID-19–positive patients with upper gastrointestinal diseases after PSM. HR, hazard ratio. Forest plots for association between (E) PPI or (F) H2RA use and risk of SARS-CoV-2 infection. The gray boxes denote the effect sizes of studies and the size of each box is proportional to the weight given to each study. The diamonds represent the pooled OR of the meta-analysis, with the tips of the diamond indicating the 95% CI. 1. Almario et al2: the OR used in the meta-analysis was the pooled OR of reporting a positive COVID-19 test associated with once-daily and twice-daily use of PPIs from subgroup analysis. 2. Lee et al3: the OR used in the meta-analysis was the pooled ORs of testing positive for COVID-19 associated with past and current PPIs use from subgroup analysis. 3. In our study, the OR of testing positive for COVID-19 associated with PPIs therapy in the PSM cohort was used in the meta-analysis. 4. Lee et al3: the OR of testing positive for COVID-19 associated with current PPIs use from subgroup analysis was used in the meta-analysis. 5 and 6. Almario et al2: the ORs of reporting a positive COVID-19 test associated with once daily and twice daily use of H2RAs from subgroup analysis were pooled using the fixed effects meta-analysis.